Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Guinea Bissau Health Bulletin.
Press releases published on October 22, 2025
HearAdvisor Announces New Guide on the Best Hearing Aids and Earplugs of 2025 with Expert Choice Awards
Rockford, Il, Oct. 22, 2025 (GLOBE NEWSWIRE) -- HearAdvisor, an independent audio performance lab, today announced the winners of its 2025 Expert Choice Awards, recognizing the best hearing aids and earplugs of the year. Now in its third year, the awards …
CVRx to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call on Nov. 5, 2025
MINNEAPOLIS, Oct. 22, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular …
Clover Health to Participate in Upcoming 2025 UBS Global Healthcare Conference
WILMINGTON, Del., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that its Chief Financial Officer, Peter Kuipers, will present at the 2025 UBS Global …
Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjögren’s Disease
CAMBRIDGE, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it will host a live webcast to present and discuss the newly disclosed …
Acrivon Therapeutics Highlights its Powerful Generative Phosphoproteomics AP3 Platform with Compelling Preclinical Data for ACR-2316 with Three Presentations at the Upcoming AACR-NCI-EORTC International Conference
AP3 Generative AI KaiSR model globally assesses drug effects on the entire intracellular protein signaling network for optimal drug design and precision medicine development Favorable ACR-2316 preclinical data, demonstrating its differentiated and superior …
Cytek Biosciences to Report Third Quarter 2025 Financial Results on November 5, 2025
FREMONT, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the third quarter 2025 after market close on Wednesday, November 5, 2025. The …
Senseonics Holdings, Inc. Schedules Third Quarter 2025 Earnings Release and Conference Call for November 5, 2025 at 4:30 P.M. Eastern Time
GERMANTOWN, Md., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people …
RxSight, Inc. to Report Third Quarter 2025 Financial Results on November 5, 2025
ALISO VIEJO, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, will report financial results for the …
PacBio to Report Third Quarter 2025 Financial Results on November 5, 2025
MENLO PARK, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its third quarter 2025 financial results on Wednesday, November 5, 2025, at 4:30 pm Eastern Time. The …
OPKO Health to Report Third Quarter 2025 Financial Results on October 29
MIAMI, Oct. 22, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and nine months ended September 30, 2025 after the close of the U.S. financial markets on Wednesday, October 29, 2025. …
Ventyx Biosciences Announces Positive Topline Results from Phase 2 Study of VTX3232 in Participants with Obesity and Cardiovascular Risk Factors
VTX3232 demonstrated significant reductions in cardiovascular risk factors, with additional benefits when combined with semaglutide VTX3232 monotherapy achieved ~80% reduction in hsCRP within the first week VTX3232 monotherapy reduced IL-6 levels at Week …
Telix Doses First Patient in SOLACE Trial for Metastatic Bone Pain
MELBOURNE, Australia and INDIANAPOLIS, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that it has dosed the first patient in a Phase 1 clinical trial of TLX090 (153Samarium (Sm)-DOTMP), a …
Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
NEW HAVEN, Conn., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that preclinical data for ARV-806, a PROTAC KRAS …
Cytokinetics to Announce Third Quarter Results on November 5, 2025
SOUTH SAN FRANCISCO, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report third quarter results on November 5, 2025 at 4:00 PM Eastern Time. Following the announcement, …
Molecular Diagnostics Market to Grow at 13.1% CAGR Through 2030
Boston, Oct. 22, 2025 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research, “Molecular Diagnostics: Technologies and Global Markets” is projected to grow from $23 billion in 2025 to $42.6 billion by the end of 2030, at a compound annual …
Newsweek and Statista Recognize America’s Best In-State Hospitals 2026
NEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Newsweek, in partnership with global data firm Statista, today announced the results of America’s Best In-State Hospitals 2026, recognizing top-performing hospitals across all 50 states for their excellence in …
Applied Food Sciences Partners with Dempsey Corporation to Accelerate Distribution of Innovative Functional Ingredients in Canada
Kerrville, Texas, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Applied Food Sciences, Inc. (AFS), a leading innovator in functional, science-backed ingredients, today announced a new strategic distribution partnership with Dempsey Corporation, a premier provider of …
Complement 3 Glomerulopathy Market Poised for Phenomenal Expansion at a CAGR of 37.2% During the Forecast Period (2025–2034) Owing to the Launch of Promising Therapies Targeting C3, C5, MASP-3, and RNAi | DelveInsight
New York, USA, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Complement 3 Glomerulopathy Market Poised for Phenomenal Expansion at a CAGR of 37.2% During the Forecast Period (2025–2034) Owing to the Launch of Promising Therapies Targeting C3, C5, MASP-3, and RNAi | …
EmblemHealth Celebrating Strong Leadership in Challenging Times
NEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) -- EmblemHealth, a not-for-profit health plan dedicated to its community mission, and LaborPress, New York’s top source for daily labor news and industry information, are proud to present the annual Heroes of Labor …